Key result
Among adults aged ≥50 years, injection site and systemic reactions were less frequent after a second mRNA COVID-19 booster than the first, and 94.8% of VAERS reports were nonserious.
Why the study?
Following FDA authorization of a second mRNA COVID-19 booster dose for adults aged 50 years and immunocompromised individuals, characterization of its safety was needed.
What is the safety profile of a second mRNA booster dose of COVID-19 vaccine in adults aged ≥50 years?
Population
286,380 v-safe registrants and 8,515 VAERS reports among US adults aged 50 years
Comparison
Second mRNA booster dose vs first booster dose
Design
Active and passive vaccine safety surveillance study
Authors
Loading...
Supports second booster safety monitoring; leaves open long-term risks and effectiveness in expanded groups.
Observational (n=286,380)
Yes
What is the safety profile of a second mRNA booster dose of COVID-19 vaccine in adults aged ≥50 years?
A second mRNA COVID-19 booster dose in adults aged ≥50 years is associated with expected local and systemic reactions that are less frequent than after the first booster, with serious adverse events being uncommon.
Hause et al. (2022) conducted an observational in COVID-19 vaccination (n=286,380). Second mRNA COVID-19 vaccine booster dose vs. First booster dose was evaluated on Adverse events (injection site and systemic reactions). Among adults aged ≥50 years, injection site and systemic reactions were less frequent after a second mRNA COVID-19 booster than the first, and 94.8% of VAERS reports were nonserious.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: